News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UK’s NICE Backs First-line Use of Johnson & Johnson’s Velcade
June 2, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Britain's healthcare cost-effectiveness watchdog NICE recommended Johnson & Johnson's (JNJ.N) drug Velcade as a first-line treatment for multiple myeloma in draft guidance issued on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
RNA editing
Wave Crashes Despite Successful RNA Editing in AATD Study
September 4, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Ionis’ Tryngolza Hits ‘Best-Case Scenario’ in Late-Stage Triglyceride Study
September 3, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Cytokinetics Soars on Aficamten’s ‘Best-in-Class’ Performance in Phase III Cardio Study
September 3, 2025
·
2 min read
·
Tristan Manalac
Podcast
CDC Faces Critical Meetings Amid COVID Vaccine Uncertainty, Plus Deals, FDA Approvals, More
September 3, 2025
·
1 min read
·
Jef Akst
